The road to chemotherapy-free treatment in chronic lymphocytic leukaemia


Por: Albiol, N, Arguello-Tomas, M, Moreno, C

Publicada: 1 nov 2021
Resumen:
Purpose of review The treatment landscape of chronic lymphocytic leukaemia (CLL) has tremendously evolved in the last decades, from chemo to chemoimmunotherapy (CIT) and, eventually, to pathway inhibitors that target critical pathways for leukaemic cells survival. Also, treatment goals are moving towards achieving undetectable minimal residual disease with little toxicity. Recent findings We performed a thorough review of the history of treatment approvals by both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This review especially focuses on therapies that are currently approved by both agencies. The indications and particular characteristics of each drug are examined. Currently available treatment approaches for CLL offer the opportunity to individualize therapy for every single patient with CLL. Inhibitors of B-cell receptor (BCR) signalling pathways and antiapoptotic proteins are nowadays the treatment of choice for most CLL patients, but CIT can be an option for younger and fit patients with low-risk disease [mutated IGHV, no del(11q) or del(17p)/TP53 mutations].

Filiaciones:
Albiol, N:
 Autonomous Univ Barcelona, Dept Hematol, Hosp Santa Creu & St Pau, Barcelona, Spain

Arguello-Tomas, M:
 Autonomous Univ Barcelona, Dept Hematol, Hosp Santa Creu & St Pau, Barcelona, Spain

Moreno, C:
 Autonomous Univ Barcelona, Dept Hematol, Hosp Santa Creu & St Pau, Barcelona, Spain
ISSN: 10408746





CURRENT OPINION IN ONCOLOGY
Editorial
LIPPINCOTT WILLIAMS & WILKINS, TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA, Estados Unidos America
Tipo de documento: Review
Volumen: 33 Número: 6
Páginas: 670-680
WOS Id: 000707391600018
ID de PubMed: 34474439

MÉTRICAS